% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

  • dgmc1999 dgmc1999 Feb 22, 2013 5:45 PM Flag

    Folotyn sales

    The acquisition of Allos was 9-6-12.

    For the first month, sales were $3.4 million. A little bit skewed due to 24 day month. Sales were $20.4 million since acquisition.

    I think this might be the diamond in the rough. This could be approx $6 million per month.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Interesting the number of neg vs. positive votes. I expected more negative.

      There is nothing neg or positive about my post. It is relating info from the 10-Q. Which basically is taking facts and displaying them here for people to have more knowledge.

      • 2 Replies to dgmc1999
      • Thanks for this information. I saw the $20.4 million number in the company's press release, stating that this total was for the 4 months since acquisition. That obviously would translate to over $60 million p/a if sales stayed flat. Considering the expanded sales force and the company's focus on these 2 drugs, it would be a surprise if that happened. I'd like to know where you found this information, though. I can't find a 10-Q posted yet for the quarter and if product sales are broken out in the 8-K I can't seem to find the right page. TIA.

      • 27M shorts don't like the current facts. And the facts are that they are screwed. Strong Folotyn sales hurt their argument that SPPI is a one trick pony that is destined for failure. Pretty pathetic that all they can do is hit the thumbs down and watch as time runs out for them.

3.77+0.02(+0.53%)Oct 27 4:00 PMEDT